Salim S. Hayek
A5084303286- COVID-19 Clinical Research Studies
- Cardiac Valve Diseases and Treatments
- Long-Term Effects of COVID-19
- Cardiac Imaging and Diagnostics
- Chemotherapy-induced cardiotoxicity and mitigation
- Cardiovascular Function and Risk Factors
- COVID-19 and healthcare impacts
- Protease and Inhibitor Mechanisms
- Renal Diseases and Glomerulopathies
- Cancer Immunotherapy and Biomarkers
- Chronic Kidney Disease and Diabetes
- Infective Endocarditis Diagnosis and Management
- Acute Myocardial Infarction Research
- Blood Pressure and Hypertension Studies
- Respiratory Support and Mechanisms
- Sepsis Diagnosis and Treatment
- Angiogenesis and VEGF in Cancer
- Heart Failure Treatment and Management
- Cardiac Structural Anomalies and Repair
- Atherosclerosis and Cardiovascular Diseases
- SARS-CoV-2 and COVID-19 Research
- Heart Rate Variability and Autonomic Control
- CAR-T cell therapy research
- Viral Infections and Immunology Research
- Peptidase Inhibition and Analysis
University of Michigan
2019-2025
Michigan Medicine
2020-2025
The University of Texas Medical Branch at Galveston
2024-2025
University Hospitals of Cleveland
2010-2025
Mercy Hospital and Medical Center
2025
Emory University
2012-2024
Michigan United
2024
American Heart Association
2022-2024
University of Michigan–Dearborn
2024
University of Thessaly
2020-2022
<h3>Importance</h3> The US is currently an epicenter of the coronavirus disease 2019 (COVID-19) pandemic, yet few national data are available on patient characteristics, treatment, and outcomes critical illness from COVID-19. <h3>Objectives</h3> To assess factors associated with death to examine interhospital variation in treatment for patients <h3>Design, Setting, Participants</h3> This multicenter cohort study assessed 2215 adults laboratory-confirmed COVID-19 who were admitted intensive...
Therapies that improve survival in critically ill patients with coronavirus disease 2019 (COVID-19) are needed. Tocilizumab, a monoclonal antibody against the interleukin 6 receptor, may counteract inflammatory cytokine release syndrome severe COVID-19 illness.
Relatively high plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) have been associated with focal segmental glomerulosclerosis and poor clinical outcomes in patients various conditions. It is unknown whether elevated suPAR normal kidney function are future decline the estimated glomerular filtration rate (eGFR) incident chronic disease.We measured 3683 persons enrolled Emory Cardiovascular Biobank (mean age, 63 years; 65% men; median level, 3040 pg per...
Significance Statement Although AKI is an important sequela of coronavirus disease 2019 (COVID-19), data on treated with RRT (AKI-RRT) in patients COVID-19 are limited. In a multicenter cohort study 3099 critically ill adults admitted to intensive care units (ICUs) at 67 hospitals across the United States, one five developed AKI-RRT, 63% whom died during hospitalization. Among who survived hospital discharge, three remained dependent and six 60 days after ICU admission. The identified...
Background— We aimed to determine the incidence, predictors, clinical characteristics, management, and outcomes of infective endocarditis (IE) after transcatheter aortic valve implantation (TAVI). Methods Results— This multicenter registry included 53 patients (mean age, 79±8 years; men, 57%) who suffered IE TAVI 7944 a mean follow-up 1.1±1.2 years (incidence, 0.67%, 0.50% within first year TAVI). Mean time from was 6 months (interquartile range, 1–14 months). Orotracheal intubation (hazard...
Acute kidney injury is common, with a major effect on morbidity and health care utilization. Soluble urokinase plasminogen activator receptor (suPAR) signaling glycoprotein thought to be involved in the pathogenesis of disease. We investigated whether high level suPAR predisposed patients acute multiple clinical contexts, we used experimental models identify mechanisms by which acts assess it as therapeutic target.We measured plasma levels preprocedurally who underwent coronary angiography...
Abstract Objectives To estimate the incidence, risk factors, and outcomes associated with in-hospital cardiac arrest cardiopulmonary resuscitation in critically ill adults coronavirus disease 2019 (covid-19). Design Multicenter cohort study. Setting Intensive care units at 68 geographically diverse hospitals across United States. Participants Critically (age ≥18 years) laboratory confirmed covid-19. Main outcome measures In-hospital within 14 days of admission to an intensive unit mortality....
Extrapulmonary manifestations of COVID-19 have gained attention due to their links clinical outcomes and potential long-term sequelae1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) displays tropism towards several organs, including the heart kidney. Whether it also directly affects liver has been debated2,3. Here we provide clinical, histopathological, molecular bioinformatic evidence for hepatic SARS-CoV-2. We find that injury, indicated by a high frequency abnormal function...
Hypercoagulability may be a key mechanism of death in patients with coronavirus disease 2019 (COVID-19).
Immune checkpoint inhibitors (ICIs) are approved for multiple cancers but can result in ICI-associated myocarditis, an infrequent life-threatening condition. Elevations cardiac biomarkers, specifically troponin-I (cTnI), troponin-T (cTnT), and creatine kinase (CK), used diagnosis. However, the association between temporal elevations of these biomarkers with disease trajectory outcomes has not been established.